img

Orlistat- drug designed to treat obesity.

Orlistat is a medicine which can help you to lose weight if you are obese or overweight. More

Sharing is caring, show love and share the thread with your friends.

Description

Orlistat is a medicine which can help you to lose weight if you are obese or overweight.

Generic Name

Orlistat- drug designed to treat obesity.

Chemical names

Orlistat; Tetrahydrolipstatin; Xenical; Alli

Brand names

Cobese, Jm-Slim, Lipocut, Lipophage, O-Trim, Obelit, Obiless, Obitrol, Olisat, Orle, Orlean, Orlica, Orlife, Orlimac, Orlitroy, Reeshape, Troyslim, Vyfat, Zerofat

IUPAC name

(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate

Pharmacokinetics

Actions

Orlistat is a reversible inhibitor of lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. As undigested triglycerides are not absorbed, the resulting caloric deficit may have a positive effect on weight control.

Dosage/Dosage form

120 mg tid with each main meal containing fat

Therapeutic uses

Anti obesity drug.

Adverse effects/Side effects

Faecal urgency and incontinence, flatulence, fatty stools or discharge, increased defecation; headache, anxiety, fatigue, menstrual irregularities; abdominal pain/discomfort.

Interaction

  • May decrease absorption of oral fat-soluble vitamins, amiodarone, propafenone.
  • May alter the effects of warfarin (monitor INR).
  • May decrease plasma levels of ciclosporin.
  • May elevate plasma levels of pravastatin.

Contraindications

Chronic malabsorption syndrome. Cholestasis. Lactation.

Storage

Store at 15-30°C (59-86°F).

Information

Molecular weight

495.7348

Molecular formula

C29H53NO5

CAS number

96829-58-2

Precautions

  • Distribute daily intake of fat over 3 main meals.
  • Fat-soluble vitamins supplements may be required during long-term therapy.
  • Discontinue use if 5% body wt loss is not achieved during the first 12 wk.
  • History of hyperoxaluria or calcium oxalate nephrolithiasis.
  • DM.
  • Pregnancy.